GRI Bio regains compliance with Nasdaq minimum bid price rule

GRI Bio, Inc.

Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).
Previously reported bid price deficiency in September 2024 filings.
Company is now in full compliance and subject to no further action from Nasdaq.

item 3.01 item 8.01 item 9.01

GRI Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001824293-25-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.